Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood

Christonikos Leventelis, Nikolaos Goutzourelas, Aikaterini Kortsinidou, Ypatios Spanidis, Georgia Toulia, Antzouletta Kampitsi, Christina Tsitsimpikou, Dimitrios Stagos, Aristidis S. Veskoukis, and Demetrios Kouretas

1Department of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, Greece
2Organization Against Drugs, 10433 Athens, Greece
3Department of Nursing, University of West Attica, 12243 Athens, Greece
4General Anticancer Hospital "Agios Savvas", 11522 Athens, Greece
5General Chemical State Laboratory of Greece, 11521 Athens, Greece

Correspondence should be addressed to Demetrios Kouretas; dkouret@uth.gr

Received 7 December 2018; Revised 11 March 2019; Accepted 17 March 2019; Published 9 April 2019

Buprenorphine and methadone are two substances widely used in the substitution treatment of patients who are addicted to opioids. Although it is known that they partly act efficiently towards this direction, there is no evidence regarding their effects on the redox status of patients, a mechanism that could potentially improve their action. Therefore, the aim of the present investigation was to examine the impact of buprenorphine and methadone, which are administered as substitutes to heroin-dependent patients on specific redox biomarkers in the blood. From the results obtained, both the buprenorphine (n = 21) and the methadone (n = 21) groups exhibited oxidative stress and compromised antioxidant defence. This was evident by the decreased glutathione (GSH) concentration and catalase activity in erythrocytes and the increased concentrations of thiobarbituric acid reactive substances (TBARS) and protein carbonyls in the plasma, while there was no significant alteration of plasma total antioxidant capacity (TAC) compared to the healthy individuals (n = 29). Furthermore, methadone revealed more severe oxidant action compared to buprenorphine. Based on relevant studies, the tested substitutes mitigate the detrimental effects of heroin on patient redox status; still it appears that they need to be boosted. Therefore, concomitant antioxidant administration could potentially enhance their beneficial action, and most probably, buprenorphine that did not induce oxidative stress in such a severe mode as methadone, on the regulation of blood redox status.

1. Introduction

Drug addiction is a serious health problem that modern society has to face. It is indicative that mortality rates due to the increasing prevalence of opioid use have risen approaching an epidemic scale in some countries [1]. According to recent epidemiological data, there is an upward trend in Europe with regard to the number of overdose deaths, and intriguingly, opioids are responsible for the 81% of them [2]. In addition, it has been reported that in the European Union, opioids are the main substances of use (i.e., 38% of all cases), whereas heroin comprises the 79% of them. There is also a serious issue of this kind in North America since there has been observed enhanced morbidity and mortality associated with the abuse of prescription opioids, heroin, and lately, the use of high-potency synthetic opioids, especially fentanyl derivatives [2].

Opioids in general have twofold inhibitory action. They act both at the presynaptic nerve terminal by inhibiting neurotransmitter release and at the postsynaptic neuron.
Specifically, they primarily block μ (mu) receptors, thus, preventing the secretion of γ-aminobutyric acid (GABA) that acts on dopaminergic neurons by inhibiting dopamine release. The inhibitory action of opioids on GABA results in increased dopamine release by dopaminergic neurons in the ventral tegmental area (VTA), which is associated with the reward system through projecting to the nucleus accumbens [3]. The latter are considered the neural mediators for food intake, sexual behavior, motivation for reward, stress-related behavior, and substance dependence [4, 5]. Some of the well-described (side) effects of opioid use are analgesia, respiratory depression, euphoria, and psychological dependence [6]. The augmentation of dopamine release appears to be responsible for addiction in opioids. Interestingly, the increase of dopamine induced by stimuli associated with pleasure that are an outcome of opioid substance use leads to memorizing signals announcing the reward. Therefore, when the dopamine system is overstimulated, the desire to repeat this experience may be at the expense of other important targets [7, 8].

There are several studies in the literature demonstrating a connection between addiction in opioids and oxidative stress in neuron cells. Noteworthy, repeated use of large opioid doses causes permanent damage to the dopamine mechanism. This is due to elevated dopamine release, hence, causing its autooxidation that generates 3,4-dihydroxyphenylacetic acid (DOPAC), a metabolite of dopamine and H₂O₂ [9–11]. Hydrogen peroxide can subsequently react with metal ions (Fe²⁺ and Cu⁺) and during the Fenton reaction generates OH radical, which is probably the most reactive free radical in the cellular environment potentially inducing oxidative stress [12–18]. Furthermore, it has been shown that the increased dopamine release through its oxidation leads to the production of quinone radicals lowering the GSH:GSSG ratio and, therefore, the available reductive equivalents [17, 19–21]. The reactive species induced by opioid use activate the Jun N-terminal kinase/stress-activated protein kinase pathway (JNP/SAPK) causing neuron cell apoptosis [22, 23]. Due to potentially high levels of dopamine oxidation, it has been hypothesized that dopaminergic neuron endings more likely maintain dopamine levels in synaptic vesicles than neutralize the dopamine oxidation resulting in neurotoxic effects [10, 24].

Buprenorphine and methadone treatment is a common practice for rehab of individuals that use addictive substances. It involves the prescription of these drugs as substitutes to the opioids that a patient is dependent on [25–28]. Buprenorphine seems to be more effective than methadone because it causes less analgesia since it is not a full agonist of μ receptors [29]. It has been also demonstrated that methadone reduces opioid tolerance and alters redox status, thus alleviating the side effects of opioids [30]. To this end, there are numerous substitution programs worldwide administering buprenorphine and methadone and it has been reported that they increase the probability of recovery for the addictive individuals [31].

To our knowledge, there is scarce evidence that methadone and buprenorphine act through redox-related mechanisms [32, 33]. However, the literature lacks observational studies regarding their effects on the redox status of individuals that are addictive to opioid substances. It is known that drug addictions have a negative impact on the systemic antioxidant defences. Therefore, the goal of the present investigation was to examine the effects of methadone and buprenorphine, when used as substitute treatments, on the redox status of patients suffering from heroin addiction.

2. Materials and Methods

2.1. Participants. Seventy-one subjects participated in the present investigation. They were randomly divided into two groups, namely, the observation group (n = 42), which includes patients being under opioid maintenance treatment (OMT) in the therapeutic units of Attica Organization Against Drugs in Greece, and the control group (n = 29) comprising healthy individuals without prior contact with substances able to induce addiction. The OMT group was further divided in the MMT (methadone maintenance treatment) (n = 21) and the BMT (buprenorphine maintenance treatment) (n = 21) groups. The participating patients were fully informed about the purpose and objectives of the study. All necessary information and safeguards were provided to ensure the confidentiality of data, and each patient signed a consent form before the study began. According to our inclusion criteria, all subjects were over 20 years of age and were long-term heroin or other opioid drug users and suffering from physical and mental dependence due to using. Participants with severe psychopathology and other serious medical problems, such as infection by human immunodeficiency virus (HIV) or hepatitis B virus (HBC), were excluded from the study. Patients with relapse to other addictive substances were not also included. In order to avoid this, all participants underwent weekly urine tests during the three-month period of the substitution treatment (i.e., methadone or buprenorphine) to rule out the use of other substances (i.e., opioids, methamphetamine, methadone, benzodiazepines, cannabis, tetrahydrocannabinol, amphetamine, and buprenorphine by one-step multidrug test kits). All subjects were found negative for substance abuse. The subjects’ demographic data of the participants in the OMT programs including age, gender, area of residence, years attending Organization Against Drugs (OKANA, Athens, Greece) programs, age started using, and duration of using addictive substances before the OMT were obtained. All applied experimental procedures were in line with the European Union Guidelines laid down in the 1964 Declaration of Helsinki and approved by the Institutional Review Board of the University of Thessaly (Larissa, Greece) and the Organization Against Drugs (Athens, Greece).

2.2. Drug Administration. Commercial methadone hydrochloride solution (10 mg/ml) and buprenorphine/buprenorphine-naloxone pills (2–8 mg) were used for regular doses. The mean daily dose of methadone was 60 mg. According to the relevant literature, methadone doses of 40–50 mg or 80–100 mg per day are effective as opioid maintenance treatments for heroin-addicted patients [34, 35]. However, given
to the packed erythrocytes; they were inverted vigorously and centrifuged (28,000 g, 5 min, 4°C). The supernatant was discarded again, and 1 ml of 5 M urea (pH = 2.3) was added; the samples were vortexed and incubated at 37°C for 15 min. They were then centrifuged (15,000 g, 3 min, 4°C), and the absorbance was monitored at 375 nm using a spectrophotometer (Hitachi U-1900; serial no. 2023-029; Hitachi, Tokyo, Japan). The determination of PC concentration was based on the millimolar extinction coefficient of DNPH (221/mmol/cm).

The assay for the determination of TBARS concentration was based on the method described by Keles et al. [39]. According to it, 100 μl of plasma (or dH2O for the blank) was mixed with 500 μl of 35% TCA (Merck KGaA, Darmstadt, Germany) and 500 μl of Tris-HCl (Sigma-Aldrich, St. Louis, MO, USA; 200 mM, pH = 7.4) and incubated at RT for 10 min. One milliliter of 2 M sodium sulfate (Na2SO4) and 55 mM of thiobarbituric acid solution were added, and the samples were incubated in a waterbath at 95°C for 45 min. The samples were cooled on ice and vortexed following the addition of 1 ml of 70% TCA. Then, they were centrifuged (15,000 g, 3 min, 25°C) and the absorbance of the supernatant was monitored at 530 nm. The calculation of the TBARS concentration was based on the molar extinction coefficient of malondialdehyde [40].

TAC measurement was based on the method described by Janaszewska and Bartosz [41]. Briefly, 20 μl of plasma (or dH2O for the blank) was added to 480 μl of sodium potasuim phosphate buffer (10 mM, pH = 7.4) and 500 μl of 0.1 mM 1,1-diphenyl-1-picrylhydrazyl radical (DPPH) and the samples were incubated in the dark at RT for 60 min. The samples were then centrifuged (20,000 g, 3 min, 25°C), and the absorbance was monitored at 520 nm. TAC determination was based on the mmol of DPPH reduced by the antioxidants present in the plasma [40].

CAT activity was determined on the basis of the method of Aebi [42] as described by Veskoukis et al. [38]. In particular, 4 μl of erythrocyte lysate (diluted 1:10) was added to 2,991 μl of sodium potassium phosphate buffer (67 mM, pH = 7.4) and the samples were incubated at 37°C for 10 min. Then, 5 μl of 30% H2O2 solution was added and the change in absorbance was immediately read at 240 nm for 130 sec. The calculation of CAT activity was based on the molar extinction coefficient of H2O2.

GSH concentration was measured based on the method of Reddy et al. [43] as described by Veskoukis et al. [38]. For this assay, 20 μl of erythrocyte lysate (or dH2O for the blank) previously treated with 5% TCA was mixed with 660 μl of sodium-potassium phosphate buffer (67 mM, pH = 8) and 330 μl of 1 mM 5,5-dithiobis-2 nitrobenzoate (DTNB; Sigma-Aldrich, Munich, Germany). The samples were incubated in the dark at RT for 45 min, and the absorbance was monitored at 412 nm. The GSH concentration was calculated on the basis of a standard curve using commercially available standards.

Total protein in plasma samples was measured using Bradford reagent. Hemoglobin concentration in erythrocyte lysates was determined with a commercially available kit.
(Drabkin) according to the manufacturer’s instructions. Each assay was performed in triplicate at two different occasions.

2.5. Statistical Analysis. Data regarding redox biomarkers were analyzed by one-way ANOVA followed by Dunnett’s test for multiple pairwise comparisons. Correlation analysis between redox biomarkers and demographic data was carried out using Pearson’s correlation coefficient. The statistical significance was set at $p < 0.05$. For all statistical analyses, SPSS software version 21.0 (SPSS Inc., Chicago, IL, USA) was used. Data are presented as the mean ± standard error of the mean (SEM).

3. Results

3.1. Demographic Data. With respect to the control group, the mean age was 36.3 ± 3.2 years old and 68.9% of the participants were men. The demographic data of the participants in the OMT programs are depicted in Table 1. In brief, the mean age was 40.5 ± 1.3 years old, 68.9% of the participants were men, they mostly lived in urban areas (i.e., 92.9%), the mean time of attending OKANA programs was 0.98 ± 0.17 years, and they mainly started using addictive substances at the age of 11-20 (i.e., 66.7%) for 11-20 years (i.e., 45.2%). Furthermore, Spearman’s correlations between the demographic data and the redox biomarkers exerted no statistical significance.

3.2. Redox Biomarkers. Regarding GSH concentration and catalase activity, they were both found significantly decreased in the group of patients as a whole compared to the control by 54% and 16%, respectively (Figure 1). According to the results on the basis of each administered substance, GSH concentration was reduced in both the BMT and MMT groups compared to the control by 51% and 58%, respectively (Figure 2). No significant difference between the BMT and MMT groups was observed. Furthermore, CAT activity decreased in both the BMT and MMT groups compared to the control by 10% and 22%, respectively. There was also a significant difference in CAT activity between the MMT and BMT groups (Figure 2). With respect to PC and TBARS concentrations, a significant increase was observed in the levels of both biomarkers in the group of patients as a whole compared to the control by 34% and 112%, respectively (Figure 3). On the basis of each administered substance, PC concentration was increased in both the BMT and MMT groups by 34% and 51%, respectively (Figure 4). TBARS concentration was increased in both the BMT and MMT groups compared to the control by 120% and 105%, respectively. No significant differences between the BMT and MMT groups in either PC or TBARS levels were noticed. Finally, there were no alterations in TAC levels between the tested groups of participants (Figures 5 and 6).

4. Discussion

The main findings of the present investigation indicate that buprenorphine and methadone, two opioid substitutes administered to heroin users in order to get into the rehab period, induce oxidative stress compared to healthy individuals. It becomes apparent, hence that although they impair the unpleasant and often inhumane side effects of heroin, they still disrupt redox balance in the blood of patients.

It is worth mentioning that methadone is a full agonist of the $\mu$-opioid receptor, whereas buprenorphine is a partial agonist of the $\mu$-opioid receptor and a $\kappa$-receptor antagonist [44, 45]. Both agents are used in substitution treatment to reduce opioid damage, which is referred to as MMT (methadone maintenance treatment) and BMT (buprenorphine maintenance treatment), respectively [46, 47]. Several studies have asserted the relation of opioid cytotoxic effects with the disruption of redox balance and have stressed the protective role of GSH. Specifically, increased production of reactive oxygen species (ROS) has been associated with heroin-induced intracellular dopamine and DOPAC [16], whereas dopamine infusion in GSH-depleted SK-N-SH neuroblastoma cells increased apoptosis, nuclear DNA fragmentation, and cell membrane lesions [48]. In line with the above studies, it has also been demonstrated that a reduction of extracellular GSH was observed when astrocytes were cultured in a dopamine-rich solution indicating that dopamine is an oxidant agent especially in the absence of GSH [20], while methamphetamine-treated rats exhibited reduced GSH concentration in the striatum [21].

The negative impact of both opioids used in the present investigation (i.e., buprenorphine and methadone) on blood antioxidant status is depicted by the results in GSH concentration and CAT activation. Specifically, they were both found reduced at the patient group compared to the healthy individuals implying that their antioxidant defence was compromised. In addition, methadone seems to have a more severe effect as indicated by the significantly lower values of catalase compared to buprenorphine. These results are supported by previous findings [49–52]. Specifically, methadone appears to have a greater impact on lowering antioxidant defence since patients under MMT have shown a depletion of GSH and CAT levels [50, 52]. Nevertheless, studies comparing heroin users and methadone-treated patients have reported that the MMT group exhibits improvement in redox biomarkers [30, 53, 54]. On the same grounds, TAC

| Table 1: Demographic data of the participants in the OMT programs ($n = 42$). |
|-----------------------------------------------|
| Age (yrs)                                      |
| $40.5 \pm 1.3$                                |
| Gender (%)                                     |
| Men (73.8)                                    |
| Women (26.2)                                  |
| Urban (92.9)                                  |
| Rural (7.1)                                   |
| Area of residence (%)                         |
| Rural (7.1)                                   |
| Urban (92.9)                                  |
| Years attending OKANA programs                |
| 0-10 (21.4)                                   |
| 11-20 (66.7)                                  |
| Age started using addictive substances (%)    |
| 21-30 (26.2)                                  |
| 31-40 (7.1)                                   |
| Years using addictive substances (%)          |
| 21-30 (21.4)                                  |
| 31-40 (11.9)                                  |

...
Figure 1: GSH concentration and catalase activity in the control group ($n = 29$) and the OMT patients as a whole ($n = 42$). **Significantly different compared to the control group ($p < 0.05$ and $p < 0.001$, respectively).

Figure 2: GSH concentration and catalase activity in the control ($n = 29$), the BMT (buprenorphine) ($n = 21$), and the MMT (methadone) ($n = 21$) groups. ****Significantly different compared to the control group ($p < 0.05$ and $p < 0.001$, respectively). #Significantly different compared to the buprenorphine group ($p < 0.05$).

Figure 3: Protein carbonyl and TBARS concentrations in the control group ($n = 29$) and the OMT patients as a whole ($n = 42$). ***Significantly different compared to the control group ($p < 0.001$).
Figure 4: Protein carbonyl and TBARS concentrations in the control \((n = 29)\), the BMT (buprenorphine) \((n = 21)\), and the MMT (methadone) \((n = 21)\) groups. \(*\ast\ast\ast\ast\ast\ast\) Significantly different compared to the control group \((p < 0.01\) and \(p < 0.001\), respectively).

Figure 5: TAC levels in the control group \((n = 29)\) and the OMT patients as a whole \((n = 42)\).

Figure 6: TAC levels in the control \((n = 29)\), the BMT (buprenorphine), \((n = 21)\) and the MMT (methadone) \((n = 21)\) groups.
is decreased after opioid administration, especially heroin [9, 55–57], but it seems that substitutes have a positive effect [9, 58] increasing the antioxidant capacity of the organism. These findings are optimistic because they support the notion that although substitute treatment induces oxidative stress, this occurs in much less extent in comparison to heroin, thus reinforcing its use at rehab programs. In addition, reduction of heroin damage by substitute treatment enhances total antioxidant activity [58]. With respect to the biomarkers illustrating the oxidative modification of biomolecules, both PC and TBARS concentrations were elevated in the MMT and BMT groups. Several studies are in line with our findings indicating that methadone and buprenorphine induce oxidative stress [55, 59]. Indeed, malondialdehyde (MDA) levels were found elevated in opioid addicts [60] and in heroin users compared to methadone-administered individuals [9, 32]. Similarly, an increase in TBARS concentration has been observed in mice following heroin administration [56], whereas no significant difference after the administration of buprenorphine in comparison to the healthy animals was observed in rats [51].

It is known that, although buprenorphine and methadone induce oxidative stress as is the case in the present study too, they do it in lower extent in comparison to opioids, such as heroin that an individual can potentially be dependent on. Comparing the two agonists, buprenorphine appears to have a less severe impact on oxidative stress keeping a higher burden of intrinsic antioxidants, a fact that is in conformity with previous results reporting that buprenorphine inhibits oxidative stress [61]. To this direction, it has been proposed that internalizing opioids (methadone, fentanyl, sufentanil) activate phospholipase D2 (PLD2) and lead to enhanced ROS generation, while noninternalizing agonists (i.e., buprenorphine) do not [62]. PLD2 activation is contributed to the endocytosis of the μ-receptor and the development of opioid tolerance [63, 64]. PLD2 is considered to play an important role not only in the membrane trafficking of the μ receptor but also in the functional selectivity of opioids at it. Furthermore, the increase of free radical generation by PLD2-activating opioids is also implicated in other signaling pathways induced by growth factors playing an important role in cell proliferation and differentiation [60]. The mechanism by which ROS mediate cell proliferation appears to be associated with the activation of extracellular signal-regulated kinase 5 and p38 MAPK, which are redox-sensitive [65]. Furthermore, the product of PLD, phosphatidic acid, has been found to lead through its interaction with the mammalian target of rapamycin (mTOR) in the release and activation of cytokines [66, 67]. Notably, it has been demonstrated that exogenous administration of antioxidants can act protectively against free radical generation induced by opioids used for maintenance treatment [32, 56].

5. Conclusion

The present investigation asserts that buprenorphine and methadone, two widely used substitutes for opioid maintenance treatment, induce oxidative stress and compromise blood antioxidant defence mechanisms. It is noteworthy that according to the findings of other relevant studies, they (especially buprenorphine) attenuate the severe oxidative impact of heroin and other opioids that cause addiction. Thus, with respect to improving the antioxidant burden of patients dependent on opioids, it appears that buprenorphine and methadone act towards the desirable direction. However, as it has been previously reported, concomitant antioxidant administration could potentially enhance their beneficial action by regulating blood redox status.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

This article was supported by the Department of Biochemistry and Biotechnology, University of Thessaly, Greece.

References

[1] J. Jones, C. Mateus, P. Malcolm, K. Brady, and S. Back, “Efficacy of ketamine in the treatment of substance use disorders: a systematic review,” Frontiers in Psychiatry, vol. 9, p. 277, 2018.

[2] European Monitoring Centre for Drugs and Drug Addiction (EMCADA), European Drug Report 2018: Trends and Developments, Publications Office of the European Union, Luxembourg, 2018.

[3] L. D. Langlois and F. S. Nugent, “Opiates and plasticity in the ventral tegmental area,” ACS Chemical Neuroscience, vol. 8, no. 9, pp. 1830–1838, 2017.

[4] C. A. Owesson-White, J. Ariansen, G. D. Stuber et al., “Neural encoding of cocaine-seeking behavior is coincident with phasic dopamine release in the accumbens core and shell,” European Journal of Neuroscience, vol. 30, no. 6, pp. 1117–1127, 2009.

[5] J. A. Kaiser, “Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse,” Annual Review of Physiology, vol. 66, no. 1, pp. 447–475, 2004.

[6] R. Ting-A-Kee and D. van der Kooy, “The neurobiology of opiate motivation,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 10, 2012.

[7] J. Cami and M. Farre, “Drug addiction,” The New England Journal of Medicine, vol. 349, no. 10, pp. 975–986, 2003.

[8] D. N. Volkow, G. J. Wang, S. J. Fowler, and D. Tomasi, “Addiction circuitry in the human brain,” Annual Review of Pharmacology and Toxicology, vol. 52, no. 1, pp. 321–336, 2012.

[9] Z. Pereska, B. Dejanova, C. Bozinovska, and L. Petkovska, “Prooxidative/antioxidative homeostasis in heroin addiction and detoxification,” Bratislavské Lekárské Listy, vol. 108, no. 9, pp. 393–398, 2007.

[10] T. G. Hastings, D. A. Lewis, and M. J. Zigmond, “Role of oxidation in the neurotoxic effects of intrastral dopamine injections,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 5, pp. 1956–1961, 1996.
C. W. Olanow and W. G. Tatton, "Etiology and pathogenesis of Parkinson’s disease," *Annual Review of Neuroscience*, vol. 22, no. 1, pp. 123–144, 1999.

C. Mylonas and D. Kouretas, "Lipid peroxidation and tissue damage," *In Vivo*, vol. 13, no. 3, pp. 295–309, 1999.

V. Chiurchiù and M. MacCarrone, "Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities," *Antioxidants and Redox Signaling*, vol. 15, no. 9, pp. 2605–2641, 2011.

B. Halliwell and J. M. C. Gutteridge, *Free Radicals in Biology and Chemistry*, Oxford Science Publications, New York, NY, USA, 6th edition, 2015.

A. S. Veskoukis, A. M. Tsatsakis, and D. Kouretas, "Diary oxidative stress and antioxidant defense with an emphasis on plant extract administration," *Cell Stress & Chaperones*, vol. 17, no. 1, pp. 11–21, 2012.

M. T. Oliveira, A. C. Rego, M. T. Morgadinho, T. R. A. Macedo, and C. R. Oliveira, "Toxic effects of opioid and stimulant drugs on undifferentiated PC12 cells," *Annals of the New York Academy of Sciences*, vol. 965, no. 1, pp. 487–496, 2002.

J. Hirrlinger, J. B. Schulz, and R. Dringen, "Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson’s disease," *Journal of Neurochemistry*, vol. 82, no. 3, pp. 458–467, 2002.

R. Von Bernhardi and J. Eugenín, "Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms," *Antioxidants and Redox Signaling*, vol. 16, no. 9, pp. 974–1031, 2012.

J. B. Schulz, J. Lindenau, J. Seyfried, and J. Dichgans, "Glutathione, oxidative stress and neurodegeneration," *European Journal of Biochemistry*, vol. 267, no. 16, pp. 4904–4911, 2000.

A. D. Rabinovic and T. Hastings, "Role of endogenous glutathione in the oxidation of dopamine," *Journal of Neurochemistry*, vol. 71, no. 5, pp. 2071–2078, 1998.

A. Moszczynska, S. Turenn, and S. J. Kish, "Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine," *Neuroscience Letters*, vol. 235, no. 1, pp. 49–52, 1998.

J. L. Cadet, S. Jayanthi, and X. Deng, "Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis," *The FASEB Journal*, vol. 17, no. 13, pp. 1775–1788, 2003.

H. Pu, X. Wang, L. Su et al., "Heroin activates ATF3 and CytC via c-Jun N-terminal kinase pathways to mediate neuronal apoptosis," *Medical Science Monitor Basic Research*, vol. 21, pp. 53–62, 2015.

M. T. Oliveira, A. C. Rego, T. R. A. Macedo, and C. R. Oliveira, "Drugs of abuse induce apoptotic features in PC12 cells," *Annals of the New York Academy of Sciences*, vol. 1010, no. 1, pp. 667–670, 2003.

E. Wu, N. El Bassel, L. Gilbert, M. Chang, and G. Sanders, "Effects of receiving additional off-site services on abstinence from illicit drug use among men on methadone: a longitudinal study," *Evaluation and Program Planning*, vol. 33, no. 4, pp. 403–409, 2009.

A. Ponizovsky, A. Grinshpoon, A. Margolis, R. Cohen, and P. Rosca, "Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine," *Addictive Behaviors*, vol. 31, no. 11, pp. 2002–2013, 2006.

H. Wittchen, S. Apelt, M. Soyka, M. Gastpar, and M. Backmund, "Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients," *Drug and Alcohol Dependence*, vol. 95, no. 3, pp. 245–257, 2008.

M. Geitona, V. Carayannii, and P. Petratos, "Economic evaluation of opioid substitution treatment in Greece," *Heroin Addiction and Related Clinical Problems*, vol. 14, no. 3, pp. 77–88, 2012.

P. J. Whelan and K. Remski, "Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds," *Journal of Neurosciences in Rural Practice*, vol. 3, no. 1, pp. 45–50, 2012.

P. Mannelli, A. Patkar, S. Rozen, W. Matson, R. Krishnan, and R. Kaddurah-Daouk, "Opioid use affects antioxidant activity and purine metabolism: preliminary results," *Human Psychopharmacology*, vol. 24, no. 8, pp. 666–675, 2009.

B. J. Yarborough, S. P. Stumbo, D. McCarty, J. Mertens, C. Weisner, and C. A. Green, "Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis," *Drug and Alcohol Dependence*, vol. 160, pp. 112–118, 2016.

A. Salarian, M. Kadkhodaei, M. Zahnmatkesh et al., "Opioid use disorder induces oxidative stress and inflammation: the attenuating effect of methadone maintenance treatment," *Iranian Journal of Psychiatry*, vol. 13, no. 1, pp. 46–54, 2018.

J. Cote and L. Montgomery, "Sublingual buprenorphine as an analgesic in chronic pain: a systematic review," *Pain Medicine*, vol. 15, no. 7, pp. 1171–1178, 2014.

E. C. Strain, G. E. Bigelow, I. A. Liebson, and M. L. Stitzer, "Moderate- vs high-dose methadone in the treatment of opioid dependence," *JAMA*, vol. 281, no. 11, pp. 1000–1005, 1999.

A. J. Saxon, Y. I. Hser, G. Woody, and W. Ling, "Medication-assisted treatment for opioid addiction: methadone and buprenorphine," *Journal of Food and Drug Analysis*, vol. 21, no. 4, pp. 569–572, 2013.

A. S. Veskoukis, E. Kerasioti, A. Priftis et al., "A battery of translational biomarkers for the assessment of the in vitro and in vivo antioxidant action of plant polyphenolic compounds: the biomarker issue," *Current Opinion in Toxicology*.

N. Patsoukis, G. Zervoudakis, N. T. Panagopoulos, C. D. Georgiou, F. Angelatou, and N. A. Matsokis, "Thiol redox state (TRS) and oxidative stress in the mouse hippocampus after pentyleneetetrazol-induced epileptic seizure," *Neuroscience Letters*, vol. 357, no. 2, pp. 83–86, 2004.

A. S. Veskoukis, A. Kyparos, V. Paschalis, and M. G. Nikolaidis, "Spectrophotometric assays for measuring redox biomarkers in blood," *Biomarkers*, vol. 21, no. 3, pp. 208–217, 2016.

M. S. Keles, S. Taysi, N. Sen, H. Aksoy, and F. Akçaý, "Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis," *The Canadian Journal of Neurological Sciences*, vol. 28, no. 2, pp. 141–143, 2001.

A. S. Veskoukis, M. G. Nikolaidis, A. Kyparos et al., "Effects of xanthine oxidase inhibition on oxidative stress and swimming performance in rats," *Applied Physiology, Nutrition, and Metabolism*, vol. 33, no. 6, pp. 1140–1154, 2008.

A. Janaszewska and G. Bartosz, "Assay of total antioxidant capacity: comparison of four methods as applied to human
blood plasma,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 62, no. 3, pp. 231–236, 2002.
[42] H. Aebi, “[13] Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984.
[43] Y. N. Reddy, S. V. Murthy, D. R. Krishna, and M. C. Prabhakar, “Role of free radicals and antioxidants in tuberculosis patients,” The Indian Journal of Tuberculosis, vol. 51, pp. 213–221, 2004.
[44] A. Ferrari, C. P. R. Coccia, A. Bertolini, and E. Sternieri, “Methadone—metabolism, pharmacokinetics and interactions,” Pharmacological Research, vol. 50, no. 6, pp. 551–559, 2004.
[45] E. C. Strain, “Pharmacology of buprenorphine,” in The Treatment of Opioid Dependence, E. C. Strain and M. L. Stitzer, Eds., pp. 213–229, Johns Hopkins Press, Baltimore, MD, USA, 2006.
[46] M. Kahan, A. Srivastava, A. Ordean, and S. Cironne, “Buprenorphine: new treatment of opioid addiction in primary care,” Canadian family physician Medecin de famille canadien, vol. 57, no. 3, pp. 281–289, 2011.
[47] J. Seifert, C. Metzner, W. Paetzold et al., “Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone,” Addiction Biology, vol. 10, no. 2, pp. 157–164, 2005.
[48] A. H. Stokes, D. Y. Lewis, L. H. Lash et al., “Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis,” Brain Research, vol. 858, no. 1, pp. 1–8, 2000.
[49] M. Hemshekhar, V. Anaparti, C. Hitcon, and N. Mookherjee, “Buprenorphine alters inflammatory and oxidative stress molecular markers in arthritis,” Mediators of Inflammation, vol. 2017, Article ID 2515408, 10 pages, 2017.
[50] M. G. Di Bello, E. Masini, C. Ioannides et al., “Erratum to: histamine release from rat mast cells induced by the metabolic activation of drugs of abuse into free radicals,” Inflammation Research, vol. 62, no. 2, p. 247, 2013.
[51] S. Saranghaldian, M. Azimi-Nezhad, R. Afshari, T. Farkhondeh, and F. Karimzehad, “Effects of buprenorphine on balance of oxidant/antioxidant system in the different ages of male rat liver,” Journal of Biochemical and Molecular Toxicology, vol. 29, no. 6, pp. 249–253, 2015.
[52] C. Aranas, A. Cutando, M. J. Ferrera et al., “Parameters of oxidative stress in saliva from diabetic and parenteral drug addict patients,” Journal of Oral Pathology and Medicine, vol. 35, no. 9, pp. 554–559, 2006.
[53] J. Diaz-Flores Estévez, F. Diaz-Flores Estévez, C. Hernández Calzadilla, E. Rodríguez Rodríguez, C. Diaz Romero, and L. Serra-Majem, “Application of linear discriminant analysis to the biochemical and haematological differentiation of opiate addicts from healthy subjects: a case–control study,” European Journal of Clinical Nutrition, vol. 58, no. 3, pp. 449–455, 2004.
[54] M. A. Rodriguez-Delgado, J. F. Diaz-Flores Estévez, F. Diaz-Flores Estevez, C. Hernandez Calzadilla, and C. Diaz Romero, “Fast determination of retinol and α-tocopherol in plasma by LC,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 5, pp. 991–997, 2002.
[55] B. Xu, Z. Wang, G. Gang et al., “Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome,” Basic Clinical Pharmacology Toxicology, vol. 99, no. 2, pp. 153–161, 2006.
[56] J. Pan, Q. Zhang, Y. Zhang, Z. Ouyang, Q. Zheng, and R. Zheng, “Oxidative stress in heroin administered mice and natural antioxidants protection,” Life Sciences, vol. 77, no. 2, pp. 183–193, 2005.
[57] A. Ghazavi, G. Mosayebi, H. Solhi, M. Rafiei, and S. M. Moazzeni, “Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers,” Immunology Letters, vol. 153, no. 1-2, pp. 22–26, 2013.
[58] M. Akhbari, R. Afshari, M.Sharifi, S. I. Hashemyn, S. Majidinia, and N. K. Tousi, ”Evaluation of the effect of diacetyl morphine on salivary factors and their changes after methadone therapy,” The Journal of Contemporary Dental Practice, vol. 15, no. 6, pp. 730–734, 2014.
[59] B. Soykut, A. Eken, O. Erdem et al., “Oxidative stress enzyme status and frequency of micronuclei in heroin addicts in Turkey,” Toxicology Mechanisms and Methods, vol. 23, no. 9, pp. 684–688, 2013.
[60] K. Najafi, S. Ahmadi, M. Rahpeyma et al., “Study of serum malondialdehyde level in opioid and methamphetamine dependent patients,” Acta Medica Iranica, vol. 55, no. 10, pp. 616–620, 2017.
[61] L. Xu and W. W. Huang, “Effect of buprenorphine transdermal patch combined with patientcontrolled intravenous analgesia on the serum pain-related biochemical indexes in elderly patients with intertrochanteric fracture,” Journal of Hainan Medical University, vol. 23, no. 17, pp. 67–70, 2017.
[62] T. Koch, A. Seifert, D. F. Wu et al., “μ-Opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2,” Journal of Neurochemistry, vol. 110, no. 4, pp. 1288–1296, 2009.
[63] T. Koch, A. Widera, K. Bartzsch et al., “Receptor endocytosis counteracts the development of opioid tolerance,” Molecular Pharmacology, vol. 67, no. 1, pp. 280–287, 2005.
[64] T. Koch, D. F. Wu, L. Q. Yang, L. O. Brandenburg, and V. Holt, “Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors,” Journal of Neurochemistry, vol. 97, no. 2, pp. 365–372, 2006.
[65] S. Okamoto, D. Krainc, K. Sherman, and S. Lipton, “Antia apoptotic role of the p38 mitogen-activated protein kinase–myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7561–7566, 2000.
[66] Y. Fang, M. Viella-Bach, R. Bachmann, A. Flanigan, and J. Chen, ”Phosphatidic acid-mediated mitogenic activation of mTOR signaling,” Science, vol. 294, no. 5548, pp. 1942–1945, 2001.
[67] H. Lim, Y. Choi, W. Park, T. Lee, S. Ryu, and S. Kim, “Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway,” Journal of Biological Chemistry, vol. 278, no. 46, pp. 45117–45127, 2003.